MOSCOW (Reuters) – Interim results from Russia’s late-stage human trial of a COVID-19 vaccine could include data from 5,000-10,000 participants, Denis Logunov, a director at the Gamaleya Institute that developed the vaccine, said on Monday.
The trial of the Sputnik V vaccine, involving 40,000 volunteers, has been under way in Moscow since the beginning of September. Interim results are expected to be published in November.
(Reporting by Polina Ivanova; Editing by Mark Heinrich)
